Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (233)	10/7/2002 1:56:27 PM
From: Czechsinthemail	Respond to of 362

I'd say buying more than $300,000 worth of stock is a fair chunk of change. But as you point out, he can afford several more chunks. With the stock trading well below net cash value, it's nice to see some insider buying. Hopefully, this will lend some support to the stock price.

To: Icebrg who wrote (233)	10/7/2002 7:07:44 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 362

He hedged his TTP stake in 08-00 with puts and calls, when price was 50-55. Bastard, never reported this. Are insiders obligated to report hedge strategy? Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned -------------------------------------------------------------------------------- 6. 4. 5. Owner- Securities Acquired (A) Amount of ship 3. or Disposed of (D) Securities Form: 7. Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of 2. 2A. Deemed Code ------------------------------ Owned at End (D) or Indirect 1. Transaction Execution (Instr. 8) (A) of Month Indirect Beneficial Title of Security Date Date, if any ------------ Amount or Price (Instr. 3 (I) Ownership (Instr. 3) (mm/dd/yy) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4) ----------------------------------------------------------------------------------------------------------------------------------- Common Stock 10/2/02 X(1) 200,000 D $51.024 300,231 D =================================================================================================================================== (Over) -------------------------------------------------------------------------------- FORM 4 (continued) Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) -------------------------------------------------------------------------------- 10. 9. Owner- Number ship of Form 2. Deriv- of Conver- 5. 7. ative Deriv- 11. sion Number of Title and Amount Secur- ative Nature or Derivative 6. of Underlying 8. ities Secur- of Exer- 4. Securities Date Securities Price Bene- ity: In- cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene- 1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner- Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr. (Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4) ----------------------------------------------------------------------------------------------------------------------------------- Call option $78.86 10/2/02 E(1) V (1) 10/2/02 10/2/02 Common 200,000 0 D (obligation to Stock sell) ---------------------------------------------------------------------------------------------------------------------------------- Put option (right to sell) $51.024 10/2/02 X(1) (1) 10/2/02 10/2/02 Common 200,000 0 D Stock =================================================================================================================================== Explanation of Responses: (1) In connection with the settlement of a put option entered into on October 2, 2000 as part of a zero-cost collar arrangement, the reporting person received, for each share of stock subject to the option, a cash amount equal to the difference between the exercise price of $51.024 per share and the market price of $1.28 per share. On the same date, the related call option expired unexercised. -------------------------------------------------------------------------------- Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned -------------------------------------------------------------------------------- 6. 4. 5. Owner- Securities Acquired (A) Amount of ship 3. or Disposed of (D) Securities Form: 7. Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of 2. 2A. Deemed Code ------------------------------ Owned at End (D) or Indirect 1. Transaction Execution (Instr. 8) (A) of Month Indirect Beneficial Title of Security Date Date, if any ------------ Amount or Price (Instr. 3 (I) Ownership (Instr. 3) (mm/dd/yy) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4) ----------------------------------------------------------------------------------------------------------------------------------- Common Stock 10/3/02 P 200,000 A $1.5107 300,231 D ===================================================================================================================================

To: Icebrg who wrote (233)	10/17/2002 8:59:44 AM
From: Icebrg	Read Replies (2) \| Respond to of 362

Novartis might not have shelved Iloperidone yet after all. Novartis open to Prexige partner, not stopped Zomaril Thursday October 17, 8:49 am ET ZURICH, Oct 17 (Reuters) - Swiss healthcare firm Novartis AG (NOVZn.VX) is still open to the idea of finding a marketing partner for its Prexige pain killing drug and will likely decide on this next year, officials at Europe's third-largest drugs group said on a conference call on Thursday. Officials said Novartis had not stopped development of its Zomaril drug for schizophrenia along with Titan Pharmaceuticals Inc (AMEX:TTP - News), and also said Novartis would start to report in U.S. dollars from the first quarter of next year.